Breaking News

Chugai Pharma Appoints CMO

April 25, 2014

Gianella-Borradori brings 20 years of R&D experience

Athos Gianella-Borradori, M.D. has been appointed chief medical officer of Chugai Pharma USA, LLC, a subsidiary of Chugai Pharmaceutical Co. of Tokyo, Japan, and member of the Roche Group.
 
Dr. Gianella-Borradori is pediatric hematologist-oncologist and executive with more than 20 years of international R&D experience focusing on translational research and clinical development of novel therapeutics. He has held senior R&D positions at Novartis, Crucell, Bavarian Nordic, Cyclacel, Merck Serono, and Clavis Pharma. 
 
Dr. Gianella-Borradori is responsible for all clinical activity in the U.S. and will provide leadership for scientific and translational committees in Japan at the parent company. He represents the company in relationships with the FDA, academia, clinical investigators and patient communities, and is responsible for increasing the awareness of Chugai to facilitate its expanding clinical activity in the U.S.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.